Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops, and commercializes branded prescription medicines. Its portfolio is concentrated in hospital acute care, gastroenterology, and oncology, where it can market to relatively concentrated prescriber bases with targeted sales teams. The company sells products such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Tacilia, and it also earns other revenue from licensing, milestone payments, and related arrangements. Cumberland combines U.S. commercial execution with international partnerships to expand access to its brands outside the United States. The business is built around branded products, lifecycle management, and selective development or acquisition of additional assets.

3,0 %

85,0 %

−6,4 %

+17,6 %

1.01

0.84

— Cumberland Pharmaceuticals Inc
%
Hospital acute care45% Injectable and inpatient-focused brands used in hospital settings for urgent or monitored treatment.
Gastroenterology20% Products used for digestive and gastrointestinal conditions, including constipation and H. pylori treatment.
Oncology supportive care15% Therapies used to support cancer patients, especially for chemotherapy-related side effects.
Anti-infective and specialty infectious disease10% Hospital-use anti-infective products for serious bacterial infections and related indications.
Other revenue and partnerships10% Milestone payments, licensing income, contract services, and other non-product revenue.

Cumberland primarily sells to wholesale pharmaceutical distributors in the United States, which then supply hospitals,...

  • U.S. pharmaceutical wholesalersprimary

    Primary buyers that purchase branded products in bulk and distribute them to hospitals, clinics, and pharmacies.

  • Hospitals and health systemsprimary

    Institutional end users for acute-care injectables such as Acetadote, Caldolor, and Vibativ, where clinical need and formulary placement drive use.

  • Payors and PBMsprimary

    Indirect customers that influence rebates, formulary inclusion, and net pricing for Cumberland's branded medicines.

  • Group purchasing organizationssecondary

    Large institutional buyers that negotiate access and pricing for hospital systems and outpatient facilities.

  • International commercial partnerssecondary

    Licensees and distributors that register and sell Cumberland products outside the U.S. in exchange for milestone or royalty economics.

Cumberland is headquartered in the United States and generates most of its commercial activity there, where it promotes...

  • •United States is the core commercial market and main source of product sales
  • •U.S. distribution logistics are handled by Cardinal Health Specialty Solutions
  • •International partners support registration and commercialization outside the U.S.
  • •China and Saudi Arabia were highlighted as recent Vibativ expansion markets
  • •Mexico approval expanded the ibuprofen product's Latin American footprint
  • •Geographic expansion can add milestone revenue but increases regulatory complexity

Cumberland’s strategy is to grow its approved branded portfolio by improving access, expanding promotion, and...

01
Grow approved brands in core specialty marketsshort-term

The company’s near-term cash generation depends on maximizing sales from its existing branded portfolio in concentrated prescriber bases.

02
Expand international partnerships and registrationsmedium-term

International commercialization can extend product life cycles and create milestone or royalty revenue without building a full foreign sales infrastructure.

03
Advance ifetroban and other development assetsmedium-term

A successful pipeline asset could diversify the company beyond mature commercial brands and reduce dependence on a small product set.

04
Pursue selective acquisitions and collaborationslong-term

External asset sourcing can replenish the portfolio and create new branded opportunities without relying solely on internal discovery.

Cumberland faces the typical risks of a branded pharmaceutical company, including generic competition, pricing...

high

Generic substitution and branded product erosion

Cumberland sells branded prescription medicines in categories where generic alternatives can quickly reduce demand and pricing power.

Scope
Kristalose and other mature brands
Materiality
high
high

Formulary and reimbursement pressure

Managed care organizations, PBMs, and hospital buyers can restrict access or demand rebates, reducing net revenue.

Scope
Hospital and specialty channels
Materiality
high
high

Distributor concentration

A small number of wholesalers represent a large share of revenue, so customer concentration can materially affect sales if purchasing patterns change.

Scope
U.S. wholesale channel
Materiality
high
high

Regulatory and compliance risk

The business depends on FDA approvals, labeling, and ongoing compliance with pharmaceutical regulations.

Scope
Approved brands and pipeline assets
Materiality
high
medium

Product liability and safety claims

Prescription medicines can trigger litigation or adverse event-related claims that create legal costs and reputational damage.

Scope
Commercialized products and clinical programs
Materiality
medium
medium

Supply chain and third-party execution

The company relies on third-party logistics, manufacturing, and international partners, which can affect inventory and launch timing.

Scope
U.S. distribution and overseas commercialization
Materiality
medium
Revenue deductions and reserves
Affects reported net sales and receivables
Other revenue recognition
Affects quarterly revenue volatility
Inventory obsolescence
Affects gross margin and operating income
Intangible assets and contingent consideration
Affects impairment risk and acquisition accounting
R&D accruals and share-based compensation
Affects operating expenses

Anebulo Pharmaceuticals, Inc.

ANEB · Pharmaceutical Preparations

Cocrystal Pharma, Inc.

COCP · Pharmaceutical Preparations

AMGEN INC

AMGN · Biological Products, (No Diagnostic Substances)

Amphastar Pharmaceuticals, Inc.

AMPH · Pharmaceutical Preparations

Adagio Medical Holdings, Inc.

ADGM · Surgical & Medical Instruments & Apparatus

Acurx Pharmaceuticals, Inc.

ACXP · Pharmaceutical Preparations

: 11/08/2026